Clinical outcomes following switch from venlafaxine ER to desvenlafaxine in nonresponders and responders
| العنوان: | Clinical outcomes following switch from venlafaxine ER to desvenlafaxine in nonresponders and responders |
|---|---|
| المؤلفون: | Christine J. Guico-Pabia, Qin Jiang, Michael E. Thase, Philip T. Ninan |
| المصدر: | Current Medical Research and Opinion. 27:1815-1826 |
| بيانات النشر: | Informa Healthcare, 2011. |
| سنة النشر: | 2011 |
| مصطلحات موضوعية: | Adult, Male, medicine.medical_specialty, Adolescent, Drug Resistance, Venlafaxine, Placebo, Placebos, Young Adult, Double-Blind Method, Rating scale, Desvenlafaxine Succinate, Internal medicine, Post-hoc analysis, medicine, Humans, Psychiatry, Depression (differential diagnoses), Aged, Depressive Disorder, Major, Drug Substitution, business.industry, Venlafaxine Hydrochloride, General Medicine, Middle Aged, Cyclohexanols, medicine.disease, Desvenlafaxine, Treatment Outcome, Tolerability, Delayed-Action Preparations, Major depressive disorder, Female, business, Algorithms, medicine.drug |
| الوصف: | This post hoc analysis examined efficacy and tolerability of open-label desvenlafaxine in patients with major depressive disorder switched from blinded placebo, venlafaxine extended release (ER), or desvenlafaxine.Patients who completed 8 weeks of double-blind therapy with placebo (n = 176), venlafaxine ER (n = 175), or desvenlafaxine (n = 143) enrolled in a 10-month, open-label extension study and received desvenlafaxine 200 to 400 mg/d. Efficacy (17-item Hamilton Depression Rating Scale [HDRS(17)]) was assessed separately for nonresponders and responders to double-blind treatment. Tolerability during the first month of open-label desvenlafaxine was assessed.Among nonresponders (n = 134) to double-blind placebo, venlafaxine ER, and desvenlafaxine, mean decreases in HDRS(17) scores were -10.9, -7.3, and -7.7, respectively; HDRS(17) response rates were 67%, 53%, and 48%, respectively. Although responders (n = 360) to double-blind placebo, venlafaxine ER, and desvenlafaxine had more modest decreases on the HDRS(17), response rates were higher (84%, 87%, and 83%, respectively). Rates of adverse events were highest during week 1, and decreased afterward for the remainder of the first month of treatment.Among nonresponders to 8 weeks of double-blind venlafaxine ER, desvenlafaxine, or placebo, 48% to 67% subsequently responded to open-label desvenlafaxine. Over 80% of responders to double-blind therapy maintained response on open-label desvenlafaxine. The switch from venlafaxine ER to desvenlafaxine was well tolerated. |
| تدمد: | 1473-4877 0300-7995 |
| DOI: | 10.1185/03007995.2011.605114 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ea6730fd6674538efddea41044054e4 https://doi.org/10.1185/03007995.2011.605114 |
| رقم الانضمام: | edsair.doi.dedup.....8ea6730fd6674538efddea41044054e4 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14734877 03007995 |
|---|---|
| DOI: | 10.1185/03007995.2011.605114 |